MHRA announces recall of Medley Pharma ranitidine tablets

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has announced a class two medicines recall for Medley Pharma’s ranitidine products.

The affected batches include the ranitidine 150mg tablets and the ranitidine 300mg tablets due to possible contamination from the impurity N-nitrosodimethylamine (NDMA) which has genotoxic and carcinogenic potential.

All unexpired stock is being recalled from pharmacies and retail stores as a precautionary measure. Both pharmacies and retailers have been advised to stop patients from acquiring the products immediately and to remove the medicine from shelves. Remaining stock should be quarantined and returned to the supplier.

According to the MHRA, the investigation into ranitidine medicines continues and further updates will be provided.

Editor's Note:

En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,

for any copyright disputes involved in the reproduced articles,

please email: Julia.Zhang@ubmsinoexpo.com to motify or remove the content.